🇪🇺 DCC-2618 in European Union

EMA authorised DCC-2618 on 18 November 2021

Marketing authorisation

EMA — authorised 18 November 2021

  • Application: EMEA/H/C/005614
  • Marketing authorisation holder: Deciphera Pharmaceuticals (Netherlands) B.V.
  • Local brand name: Qinlock
  • Indication: Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
  • Pathway: orphan
  • Status: approved

Read official source →

DCC-2618 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is DCC-2618 approved in European Union?

Yes. EMA authorised it on 18 November 2021.

Who is the marketing authorisation holder for DCC-2618 in European Union?

Deciphera Pharmaceuticals (Netherlands) B.V. holds the EU marketing authorisation.